Facebook
X
LinkedIn
Forward
Advanced Prostate Cancer Clinical Trial Research Webinar Series (2025)
This webinar series was developed in support of the objectives of the AUA Clinical Trials Collective™.
Prostate cancer is the second leading cause of cancer death in men in the United States. Through clinical research advancements, treatments are now available that achieve a relative 5-year survival rate for prostate cancer diagnosed in its earliest stages of over 99%. Unfortunately, the 5-year survival rate for advanced or metastatic prostate cancer significantly decreases to 37%. For the advanced prostate cancer patient population, developing therapies currently in early to late phase clinical trials are emerging that offer optimism for increased survival and improved quality of life. These therapies can only be accessed through urologist participation in clinical trial research.
This webinar series aims to provide urologists with the knowledge and tools to increase their competence and performance in successfully establishing and completing meaningful clinical trial research exploring new and emerging therapies for the treatment of advanced prostate cancer at their clinical practice site.
Acknowledgements
Support provided by an endowment from Chesapeake Urology Associates.
About the AUA Clinical Trials Collective™
The AUA Clinical Trials Collective™ (AUACTC™) was formed in 2024. The mission of the AUACTC™ is to address and overcome the challenges faced by clinical trials. This activity was developed in support of the educational needs identified by the AUACTC™.
Target Audience
This series of research continuing medical education activities is designed for:
- Residents/Fellows
- Urologists
- Clinical Research Coordinators
- Other Healthcare Professionals
Research Education, Conferences, and Communications Committee (RECCC) Disclosures:
Conflict of Interest Review Work Group Disclosures:
COI Review Workgroup DTL 2025.pdf
AUA Office of Research Staff has nothing to disclose.
All relevant financial relationships have been mitigated.
AUA ACCREDITATION INFORMATION
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates these live activities for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible company (formerly commercial interests) during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA must determine if the individual’s relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.
Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of relevant financial relationships that result in conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.
Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.